Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -0.1x - -0.1x | -0.1x |
| Historical Pb Multiple | -10.5x - 0.0x | -1.3x |
| Fair Value | $0.045 - $0.049 | $0.047 |
| Upside | -10.9% - -1.6% | -6.3% |
| Benchmarks | - | Full Ticker |
| CareDx, Inc | - | NasdaqGM:CDNA |
| iTeos Therapeutics, Inc. | - | NasdaqGM:ITOS |
| PTC Therapeutics, Inc. | - | NasdaqGS:PTCT |
| Fate Therapeutics, Inc. | - | NasdaqGM:FATE |
| Agios Pharmaceuticals, Inc. | - | NasdaqGS:AGIO |
| Regen BioPharma, Inc. | - | OTCPK:RGBP |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| CDNA | ITOS | PTCT | FATE | AGIO | RGBP | |||
| NasdaqGM:CDNA | NasdaqGM:ITOS | NasdaqGS:PTCT | NasdaqGM:FATE | NasdaqGS:AGIO | OTCPK:RGBP | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 127.6% | -19.3% | 42.0% | -15.7% | 291.4% | -184.7% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -23.1% | -135.3% | -84.6% | -711.1% | -3975.2% | 54.2% | ||
| Prior Fiscal Year | -67.9% | -894.3% | -66.8% | -253.3% | -1312.6% | 432.7% | ||
| Latest Fiscal Year | 15.7% | -384.0% | -45.0% | -1366.5% | 1845.9% | -366.6% | ||
| Latest Twelve Months | 15.7% | -384.0% | -45.0% | -1366.5% | 1845.9% | -366.6% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -18.7% | 1.5% | -6712.9% | -42.7% | -28.6% | NA | ||
| Prior Fiscal Year | -55.0% | -18.2% | NM | -37.8% | -36.8% | NM | ||
| Latest Twelve Months | 16.4% | -23.1% | NM | -54.2% | 57.3% | NM | ||
| Next Fiscal Year | 8.9% | -35.0% | 20.6% | -94.1% | -32.1% | #NUM! | ||
| Two Fiscal Years Forward | 14.3% | -57.9% | 14.4% | -5647.2% | -40.7% | 15.4% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 2.9x | 6.5x | 5.3x | 6.6x | 45.6x | 2.2x | ||
| Price / LTM EPS | 18.4x | -1.7x | -11.8x | -0.5x | 2.5x | -0.6x | ||
| Price / Book | 2.6x | 0.4x | -3.9x | 0.3x | 1.1x | -0.1x | ||
| Price / Fwd Book | 2.5x | 0.6x | -3.2x | 0.8x | 1.6x | -0.1x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -3.9x | 0.4x | 2.6x | |||||
| Historical P/B Ratio | -10.5x | -1.3x | 0.0x | |||||
| Selected P/B Multiple | -0.1x | -0.1x | -0.1x | |||||
| (x) Book Value | (5) | (5) | (5) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | CDNA | ITOS | PTCT | FATE | AGIO | RGBP | |
| Value of Common Equity | 995 | 241 | 4,278 | 97 | 1,735 | 1 | |
| (/) Shares Outstanding | 55.4 | 38.2 | 78.9 | 114.6 | 57.3 | 10.5 | |
| Implied Stock Price | 17.96 | 6.32 | 54.24 | 0.85 | 30.28 | 0.05 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 17.96 | 6.32 | 54.24 | 0.85 | 30.28 | 0.05 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |